ClinicalTrials.gg
RecruitingNCT07176936Updated Mar 27, 2026

Improving Speech in Noise Using Noninvasive Stimulation

An interventional study of Cymba Conchae stimulation and Earlobe stimulation in Traumatic Brain Injury and Hearing Loss, sponsored by University of Florida. Recruiting at 1 site in United States. Open to participants aged 25 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.

Sponsored by University of Florida · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
25 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 909 studies in Brain Injuries, Traumatic with a site in United States — 212 open to participants now, 250 under way, 5 of them phase 3. Brain Injuries, Traumatic · United States.

Planned enrollment
304th of 650
55 · median 50
Started
2026
with 64 others
No phase
441 of 909
111 open now
Primary completion
2027-07
later than 126 of 249 live
Registered
839th of 909
by date

Among the 909 studies in Brain Injuries, Traumatic with a site in United States, this one is the 304th largest by planned enrollment of the 650 interventional ones that give a count, is one of 65 that started in 2026, is one of 441 with no phase, reaches primary completion later than 126 of the 249 other live ones, and was the 839th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

212 of the 909 studies in Brain Injuries, Traumatic with a site in United States are open now. Recruiting first, the newest first:

207 more — sign in →

All 212 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 25 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 909 studies in Brain Injuries, Traumatic with a site in United States, or all of them as a file.
02

Study summary

Traumatic brain injury, a common injury in military service personnel, often leads to poor processing of speech in noisy environments. The goal of the current study is to better understand the brain basis for this difficulty and evaluate a new approach to improving speech in noise perception.

03

Conditions studied

  • Traumatic Brain Injury
  • Hearing Loss
04

Who can participate

Ages eligible
25 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 25-55 years old
  • Proficiency in English
  • TBI group: history of traumatic brain injury by blast or physical trauma
  • Normal hearing group: no history of traumatic brain injury

Exclusion criteria

Exclusion Criteria:

  • Other neurological diseases or related conditions will be excluded (e.g., large vessel stroke, seizures). We will exclude patients with severe medical diseases that may be associated with impaired cognition (e.g., heart failure, dialysis dependent kidney disease, brain cancer). Further, psychiatric diseases that are unlikely to be related to trauma will be excluded (e.g., schizophrenia).

Patients with histories of severe psychiatric disease prior to trauma exposure will be excluded.

  • Current illicit or prescription drug abuse (within the last two months)
  • Any taVNS , including but not limited to the presence of unremovable metal in the left ear, known heart conditions, medications that influence neurotransmitters thought to be critical for vagus nerve stimulation (norepinephrine, acetylcholine, and serotonin), or implanted medical devices such as a pacemaker.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
55 participants (estimated)

Study arms

  • Other
    Treatment A vs Treatment B

    Participants will receive the stimulation at location A and then receive stimulation at location B, both on the outer ear.

    Device: Cymba Conchae stimulation · Device: Earlobe stimulation

  • Other
    Treatment B then Treatment A

    Participants will receive the stimulation at location B and then receive stimulation at location A, both on the outer ear.

    Device: Cymba Conchae stimulation · Device: Earlobe stimulation

Interventions

  • DeviceCymba Conchae stimulation

    Electrical stimulation applied to the cymba conchae region of the outer ear

    Also known as: Treatment A

  • DeviceEarlobe stimulation

    Electrical stimulation applied to the earlobe region of the outer ear

    Also known as: Treatment B

06

What researchers measure

Primary outcomes

  1. Safety and feasibility

    quantify attrition as well as frequency and severity of adverse events

    Time frame: From enrollment to the end of treatment is between 2 days and 2 weeks.

Secondary outcomes

  1. Speech in Noise performance

    Percent correct on a speech in noise perception task when receiving Treatment A compared to Treatment B

    Time frame: Baseline and one week

  2. Brain response patterns

    Pattern of brain response while listening to speech in background noise while receiving Treatment A compared to Treatment B

    Time frame: Baseline and one week

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — De-identified data will be shared at the time of data publication

Supporting information: Study protocol, Informed consent form

Time frame: Data will be shared at the time of publication and will be available indefinitely

Access criteria: Data and protocols will be shared openly.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Jul 2027, 16 months after the start.

Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 16 months is below that.

Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2025
First posted
Sep 16, 2025
StartActual
Mar 21, 2026
Primary completionEst.
Jul 31, 2027
CompletionEst.
Aug 31, 2027
Last update
Mar 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07176936
Collaborators
Congressionally Directed Medical Research Programs
Responsible party
Sponsor
First posted
Sep 16, 2025
Start date
Mar 21, 2026
Primary completion
Jul 31, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Mar 27, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion